國家衛生研究院 NHRI:Item 3990099045/14372
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 851812      Online Users : 1093
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/14372


    Title: Trial Designs for integrating novel therapeutics into the management of intermediate-stage hepatocellular carcinoma
    Authors: Su, YY;Liu, YS;Hsiao, CF;Hsu, C;Chen, LT
    Contributors: National Institute of Cancer Research;Institute of Population Health Sciences
    Abstract: Intermediate-stage hepatocellular carcinoma (HCC) consists of heterogeneous groups of patients in terms of tumor burden and organ function reserves. Although liver-directed therapy (LDT), including trans-catheter arterial chemoembolization, radio-frequency ablation or even surgical resection, is the recommended frontline treatment modality, intrahepatic and distant failures are common. The recent advances in systemic treatment, notably the introduction of immune checkpoint inhibitor (ICI)-based therapy, have significantly improved the objective tumor response rate, quality of response and overall survival in patients with recurrent and advanced HCC. Whether the combination of systemic treatment and LDT can further improve the outcome of patients with intermediate-stage HCC is currently being extensively evaluated. In this article, the recent clinical trials incorporating different ICI -based combinations with different LDT for intermediate-stage HCC were reviewed focusing on trial design issues, including patient selection, endpoint definition, and biomarker development. The strength and caveats of different combination strategies and novel biomarker development were discussed.
    Date: 2022-06-02
    Relation: Journal of Hepatocellular Carcinoma. 2022 Jun 2;9:517-536.
    Link to: http://dx.doi.org/10.2147/JHC.S220978
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2253-5969&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000809419300004
    Appears in Collections:[Li-Tzong Chen] Periodical Articles
    [Yung-Yeh Su] Periodical Articles
    [Chin-Fu Hsiao] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    ISI000809419300004.pdf3407KbAdobe PDF159View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback